The management team of Juno Pharmaceuticals Inc. (Juno) is pleased to announce the launch of Juno OTC Inc. (Juno OTC).

Headquartered in Canada, Juno is an international specialty pharmaceutical and medical devices group that focuses on meeting the various product needs of physicians, pharmacy chains, and patients alike across its active markets. Juno was founded in 2011 and has grown rapidly over the past six years, currently holding offices in the UK, EU, Australia, and South Africa.

The launch of Juno OTC provides the group with an excellent opportunity to fill some of the most pressing OTC product and service needs currently present in the Canadian retail pharmacy market. Juno’s principals are confident that their extensive knowledge of the Canadian marketplace, their experience in the OTC business and their many longstanding relationships with both domestic retail partners and global product suppliers will serve the group extremely well in its latest endeavor.

Commenting on the launch of Juno OTC, Ian Jacobson, Chief Executive Officer of Juno said:

“Juno is at an exciting juncture in its development. Having already established strong commercial footprints in the hospital and retail prescription spaces, the launch of Juno OTC provides us with an excellent opportunity to diversify our business into a new vertical. Our management team has decades of experience working alongside and supporting all of the leading retail pharmacy chains in Canada and we are confident that our extensive relationships with these industry partners will prove to be an excellent platform for rapid growth.”

For further information please contact:

Jesse Buckstein, Director of Corporate Development

Tel: +1 905 881 4410 x203

Email: jesse.buckstein@junopharm.com

About Juno

Juno Pharmaceuticals Inc. is an international specialty pharmaceutical company with operations in Canada, the UK, EU, Australia, and South Africa. Juno works closely with its portfolio companies and global network of product suppliers to identify and in-license value-added and differentiated specialty generics, brands and medical devices to ensure that customers and patient groups alike across Juno’s territories have access to the medicines they require.

Juno Pharmaceuticals is excited to announce it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix^® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately and it is hoped that this product will be registered in 2016.

In Australia over 2,500 people are diagnosed each year with bladder cancer, and unfortunately over 1,000 people die.

Hexvix^®is designed to selectively target malignant cells in the bladder and induce fluorescence during a cystoscopic procedure using a blue-light enabled cystoscope. Using Hexvix^® as an adjunct to standard white-light cystoscopy enables the urologist to better detect and remove lesions. Hexvix^® is currently approved in Europe and the USA.

For more information please visit www.junopharm.com.au.

MELBOURNE, AUSTRALIA–Celgene Pty and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia.

Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia.

“By combining forces with Juno Pharmaceuticals, we are complementing our innovative product with a strong national key account management team that has relationships across the hospital market,” said George Varkanis, Celgene Vice President and Managing Director (Australia and New Zealand).

The partnership continues the trend for Juno Pharmaceuticals in partnering with leading global pharmaceutical companies. It follows a recent announcement that Juno Pharmaceuticals made with Photocure ASA to bring the unique product Hexvix® to the Australian and New Zealand markets.

“We look forward to delivering a strong partnership model with Celgene on Vidaza® and exploring any opportunities that exist throughout the products lifecycle,” said Juno Pharmaceuticals CEO George Katsanos.

Financial details of the joint venture were not disclosed.

For more information please visit www.junopharm.com.au.

We are pleased to announce the launch of our new product Lecicarbon C Suppositories, which can be used in children under the age of 12 compared to Lecicarbon A, also marketed by Aspire Pharma in the UK, which can be used in adults and children over the age of 12. Lecicarbon C is a suppository laxative containing sodium hydrogen carbonate and sodium dihydrogen phosphate, which is indicated for the treatment of all forms of frequent constipation.

To find out more about Lecicarbon C, please email info@aspirepharma.co.uk or ring +44 (0) 1730 231148+44 (0) 1730 231148.

We are pleased to announce the launch of Brinzolamide 10mg/ml Eye Drops, the newest product to be added to Aspire Pharma's product portfolio in the UK. Brinzolamide Eye Drops are used to decrease elevated intraocular pressure in ocular hypertension or open-angle glaucoma in adults. Brinzolamide Eye Drops can be used as a monotherapy in patients in whom beta-blockers are contraindicated, or as an adjunctive therapy to beta-blockers or prostaglandin analogues.

To find out more about Brinzolamide Eye Drops, please email info@aspirepharma.co.uk or ring +44 (0) 1730 231148+44 (0) 1730 231148.

Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Category 1 New Generic Medicine application in March 2015:

TRANEXAMIC ACID JUNO tranexamic acid 500mg/5mL and 1000mg/10mL solution for injection ampoule was listed on the ARTG on, 02 March 2015. Presented in a clear glass ampoule with a shelf life of 2 years, TRANEXAMIC ACID JUNO, is indicated in adults for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. In Paediatrics, TRANEXAMIC ACID JUNO is indicated for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

For more information please visit www.junopharm.com.au.